Who owns CTOR?
Institutional ownership of Citius Oncology Inc. from Form 13F, Q2 2026
19 institutional managers reported holding Citius Oncology Inc. (CTOR) in Form 13F filings for Q2 2026, with 14,145,277 shares worth $9.2M. The largest reported holder was Armistice Capital, LLC. Managers that filed both quarters cut a net 102,547 shares (-0.7%). 7 opened new positions and 2 sold out.
- Funds holding
- 19
- Value held
- $9.2M
- New / sold out
- 7 / 2
- Net shares, same filers
- -0.7%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of CTOR
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Armistice Capital, LLC | $5.7M | 61.5% | 8,705,589 | Trimmed |
| Bank of America Corp | $2.5M | 27.1% | 3,835,160 | Unchanged |
| Vanguard Capital Management LLC | $355K | 3.9% | 546,325 | Added |
| UBS Group AG | $218K | 2.4% | 334,619 | Added |
| Geode Capital Management, LLC | $160K | 1.7% | 245,407 | Trimmed |
| Vanguard Fiduciary Trust Co | $79K | 0.9% | 121,910 | Unchanged |
| IFP Advisors, Inc | $70K | 0.8% | 107,424 | Unchanged |
| Citadel Advisors LLC | $59K | 0.6% | 90,586 | New |
| Northern Trust Corp | $30K | 0.3% | 45,746 | Unchanged |
| State Street Corp | $28K | 0.3% | 42,900 | Unchanged |
| Virtu Financial LLC | $14K | 0.2% | 21,877 | New |
| XTX Topco Ltd | $13K | 0.1% | 20,638 | New |
| Tower Research Capital LLC (TRC) | $9K | 0.1% | 13,816 | New |
| Arkadios Wealth Advisors | $8K | 0.1% | 11,666 | Unchanged |
| Osaic Holdings, Inc. | $650 | 0.0% | 1,000 | Trimmed |
| Wells Fargo & Company | $325 | 0.0% | 500 | New |
| Barclays PLC | $59 | 0.0% | 90 | New |
| Morgan Stanley | $15 | 0.0% | 23 | New |
| Caitong International Asset Management Co., Ltd | $1 | 0.0% | 1 | Unchanged |
Share of 13F holdings is each fund's shares as a share of the 14,145,277 CTOR shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- UBS Group AG Added+$194K
- Citadel Advisors LLC New+$59K
- Virtu Financial LLC New+$14K
- XTX Topco Ltd New+$13K
- Tower Research Capital LLC (TRC) New+$9K
- Vanguard Capital Management LLC Added+$7K
- Wells Fargo & Company New+$325
- Barclays PLC New+$59
- Morgan Stanley New+$15
Biggest sellers in Q2 2026
- Armistice Capital, LLC Trimmed-$314K
- BlackRock, Inc. Sold out-$29K
- Geode Capital Management, LLC Trimmed-$13K
- Osaic Holdings, Inc. Trimmed-$6K
- Royal Bank of Canada Sold out-$115
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $297K and sold $362K; 2 added and 3 trimmed.
Schedule 13D and 13G filings on CTOR
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2025-11-14ARMISTICE CAPITAL, LLC SCHEDULE 13G filed by Citius Oncology Inc.Schedule 13G
Questions about CTOR ownership
- Who owns CTOR stock?
- 19 institutional investment managers reported CTOR positions in their Form 13F filings for Q2 2026, holding 14,145,277 shares worth $9.2M in total. Armistice Capital, LLC reported the largest position.
- Are funds buying or selling CTOR?
- In Q2 2026, 7 managers opened new CTOR positions, 2 added, 3 trimmed and 2 sold out. Managers that filed in both quarters sold a net 102,547 shares.
- How current is this CTOR institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to CTOR by CUSIP. Options are left out. CTOR news and filings · CTOR insider trades · Top funds